MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

MannKind (MNKD) PT Raised to $6.50 at Oppenheimer

February 28, 2024 8:24 AM EST

Oppenheimer analyst Steven Lichtman raised the price target on MannKind (NASDAQ: MNKD) to $6.50 (from $5.50) while maintaining a Outperform rating.

The analyst comments "MNKD's 4Q23 sales of $58.5M were ahead of our/Street's $52.8M/$53.5ME. Versus our estimate, the beat was driven by... More